Saturday 17 October 2026
Export WVE’s income statement to Excel — free account
WAVE Life Sciences Ltd.
In the quarter to June 2026, revenue fell 73.9%, EPS fell 9.68% and free cash flow fell 17.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.12
0.07
−2.19%
Follow WVE
WAVE Life Sciences Ltd. (WVE) P/E ratio
WAVE Life Sciences Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 39 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AVTX Avalo Therapeutics, Inc. compare | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| SLDB Solid Biosciences Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. | n/m |
| PRME Prime Medicine, Inc. compare | n/m |
| ZVRA Zevra Therapeutics, Inc. compare | 10.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)